MXPA03006988A - Factor de crecimiento de queratinocitos (kgf) modificado con inmunogenicidad reducida. - Google Patents

Factor de crecimiento de queratinocitos (kgf) modificado con inmunogenicidad reducida.

Info

Publication number
MXPA03006988A
MXPA03006988A MXPA03006988A MXPA03006988A MXPA03006988A MX PA03006988 A MXPA03006988 A MX PA03006988A MX PA03006988 A MXPA03006988 A MX PA03006988A MX PA03006988 A MXPA03006988 A MX PA03006988A MX PA03006988 A MXPA03006988 A MX PA03006988A
Authority
MX
Mexico
Prior art keywords
kgf
growth factor
keratinocyte growth
reduced immunogenicity
modified
Prior art date
Application number
MXPA03006988A
Other languages
English (en)
Inventor
Graham Carter
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MXPA03006988A publication Critical patent/MXPA03006988A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
MXPA03006988A 2001-02-06 2002-02-05 Factor de crecimiento de queratinocitos (kgf) modificado con inmunogenicidad reducida. MXPA03006988A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01102574 2001-02-06
EP01103954 2001-02-19
PCT/EP2002/001175 WO2002062842A1 (en) 2001-02-06 2002-02-05 Modified keratinocyte growth factor (kgf) with reduced immunogenicity

Publications (1)

Publication Number Publication Date
MXPA03006988A true MXPA03006988A (es) 2003-11-18

Family

ID=26076458

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03006988A MXPA03006988A (es) 2001-02-06 2002-02-05 Factor de crecimiento de queratinocitos (kgf) modificado con inmunogenicidad reducida.

Country Status (12)

Country Link
US (1) US20040063634A1 (es)
EP (1) EP1360201A1 (es)
JP (1) JP2004526437A (es)
KR (1) KR20030074791A (es)
CN (1) CN1491231A (es)
BR (1) BR0207017A (es)
CA (1) CA2437270A1 (es)
HU (1) HUP0303150A2 (es)
MX (1) MXPA03006988A (es)
PL (1) PL362397A1 (es)
RU (1) RU2003125643A (es)
WO (1) WO2002062842A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161700A1 (en) * 2004-12-28 2007-07-12 Kowa Company, Ltd. Inhibitor for the formation of y-secretase complex
US20070184487A1 (en) * 2005-07-12 2007-08-09 Baynes Brian M Compositions and methods for design of non-immunogenic proteins
CA2691539C (en) * 2007-06-21 2014-08-26 Angelica Therapeutics, Inc. Modified toxins
EP2268297A4 (en) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc MODIFIED TOXINS
US10059750B2 (en) 2013-03-15 2018-08-28 Angelica Therapeutics, Inc. Modified toxins
CA2928526A1 (en) 2013-11-01 2015-05-07 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109122A (en) * 1993-03-26 2004-07-25 Amgen Inc Use of products from a keratinocytic growth factor for the preparation of medicinal preparations
HUT78050A (hu) * 1994-10-13 1999-07-28 Amgen Inc. Cukorbetegség kezelése KGF felhasználásával
IL115605A (en) * 1994-10-13 2003-06-24 Amgen Inc Method for purifying keratinocyte growth factors
US5858977A (en) * 1994-10-13 1999-01-12 Amgen Inc. Method of treating diabetes mellitus using KGF
JP2002512624A (ja) * 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
WO2000034317A2 (en) * 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins

Also Published As

Publication number Publication date
PL362397A1 (en) 2004-11-02
EP1360201A1 (en) 2003-11-12
CN1491231A (zh) 2004-04-21
JP2004526437A (ja) 2004-09-02
WO2002062842A1 (en) 2002-08-15
KR20030074791A (ko) 2003-09-19
CA2437270A1 (en) 2002-08-15
US20040063634A1 (en) 2004-04-01
BR0207017A (pt) 2004-02-03
HUP0303150A2 (hu) 2003-12-29
RU2003125643A (ru) 2005-01-20

Similar Documents

Publication Publication Date Title
MXPA03003375A (es) Compresor lineal.
MXPA03007323A (es) Proteinas artificiales con inmunogenicidad reducida.
ZA200208561B (en) Hydraulischer druckverstarker.
EG23361A (en) High utility tissue.
MXPA03008310A (es) Interferon beta modificado con inmunogenicidad reducida.
MXPA03007693A (es) Composicion para la piel.
MXPA03006603A (es) Agonista de subtipo de receptor 5-ht1a.
HK1050610A1 (en) Microemulsion aerosol composition.
MXPA03003376A (es) Celda.
MXPA03006989A (es) Leptina modificada con inmunogenicidad reducida.
EG23378A (en) Composition.
MXPA03007838A (es) Interferon alfa modificado con inmunogenicidad reducida.
MXPA03006988A (es) Factor de crecimiento de queratinocitos (kgf) modificado con inmunogenicidad reducida.
AU2002361550A1 (en) Keratinocyte derived interferon
MXPA03008402A (es) Insulina modificada con inmunogenicidad reducida.
AUPR414701A0 (en) Alpha 1,3 galactosyltransferase
AU2002318513A1 (en) Novel neurotrophic factors
AUPR477201A0 (en) Modified keratoprosthesis
ZA200205222B (en) Crystal growth.
AUPR246301A0 (en) F.l.o.e.s, s.p.l.s.d
AU2002258620A1 (en) (oxo-pyrazolo(1,5a)pyrimidin-2-yl)alkyl-carboxamides
MXPA03008086A (es) Protamina modificada con inmunogenicidad reducida.
AUPR437901A0 (en) Mail no.
GB0130116D0 (en) Gene linkage
ZA200100556B (en) Envelope.